[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055305":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":14,"responsibleParty":7,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":37,"phases":38,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":48,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":53,"locationsCount":55},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Levocarnitine",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Adefovir dipivoxil",[15],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":7},"Gilead Sciences Inc","Foster City","California","94404","United States","US",{"type":23,"coordinates":24},"Point",[25,26],-122.27108,37.55855,{"lat":26,"lon":25},"100055305","safety-and-effectiveness-of-giving-adefovir-preveon-plus-other-anti-hiv-drugs-to-hiv-infected-patients-who-have-not-responded-to-other-anti-hiv-drug-combinations-100055305",false,"NCT00002398","Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations","A Randomized, Open-Label Expanded Access Program to Evaluate the Safety of Preveon (Adefovir Dipivoxil) at Two Dose Levels When Used in Combination With Other Antiretroviral Agents for the Treatment of Patients With HIV Infection Who Have Failed Other Antiretroviral Therapy and Have Limited Treatment Options","Inclusion Criteria\n\nYou may be eligible for this study if you:\n\n* Are HIV-positive.\n* Have a CD4 cell count of 50 cells\u002Fmm3 or less within the past 2 months.\n* Have a viral load (level of HIV in the body) of 30,000 copies\u002Fml or more within the past 2 months.\n* Are at least 13 years old (need consent of parent or guardian if under 18).\n* Have failed to respond to an anti-HIV drug combination that included at least 2 nucleoside reverse transcriptase inhibitors and at least 1 protease inhibitor (PI).\n* Do not have any other anti-HIV treatment options left.\n* Agree to use effective methods of birth control during the study.\n\nExclusion Criteria\n\nYou will not be eligible for this study if you:\n\n* Have certain serious medical conditions that would prevent you from completing the study, including serious kidney disorders.\n* Have taken certain medications, including certain treatments for opportunistic (HIV-related) diseases.\n* Are pregnant or breast-feeding.","ALL","13 Years","INTERVENTIONAL",[39],"NA","The purpose of this study is to see if it is safe and effective to give adefovir plus other anti-HIV drugs to HIV-infected patients who have failed other anti-HIV drug combinations. This study will try to make adefovir available to all AIDS patients who need it.\n\nSome patients do not respond to anti-HIV drug combinations, even when different combinations are tried. Adefovir may be able to help these patients fight HIV.",[42],"HIV Infections",[44,45,46,47],"HIV-1","Acquired Immunodeficiency Syndrome","Adenine","Anti-HIV Agents","COMPLETED","2005-06-23",{"date":51,"type":52},"2005-06-24","ESTIMATED",{"name":54,"class":6},"Gilead Sciences",1]